HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

Am J Physiol Heart Circ Physiol 292: H838-H845, 2007. First published September 29, 2006; doi:10.1152/ajpheart.00615.2006
0363-6135/07 $8.00

This Article Free upon publication Full Text Full Text (PDF) All Versions of this Article: 292/2/H838    most recent 00615.2006v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (3) Citing Articles via Google Scholar Google Scholar Articles by Luckey, S. W. Articles by Leinwand, L. A. Search for Related Content PubMed PubMed Citation Articles by Luckey, S. W. Articles by Leinwand, L. A.

Blocking cardiac growth in hypertrophic cardiomyopathy induces cardiac dysfunction and decreased survival only in males

¹Department of Molecular, Cellular, and Developmental Biology, University of Colorado, Boulder, Colorado; ²Max-Planck Institut fuer Entwicklungsbiologie, Tuebingen, Germany; and ³Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, Texas

Submitted 9 June 2006 ; accepted in final form 21 September 2006

Mutations in myosin heavy chain (MyHC) can cause hypertrophic cardiomyopathy (HCM) that is characterized by hypertrophy, histopathology, contractile dysfunction, and sudden death. The signaling pathways involved in the pathology of HCM have not been elucidated, and an unresolved question is whether blocking hypertrophic growth in HCM may be maladaptive or beneficial. To address these questions, a mouse model of HCM was crossed with an antihypertrophic mouse model of constitutive activated glycogen synthase kinase-3 (caGSK-3). Active GSK-3 blocked cardiac hypertrophy in both male and female HCM mice. However, doubly transgenic males (HCM/GSK-3) demonstrated depressed contractile function, reduced sarcoplasmic (endo) reticulum Ca²⁺-ATPase (SERCA) expression, elevated atrial natriuretic factor (ANF) expression, and premature death. In contrast, female HCM/GSK-3 double transgenic mice exhibited similar cardiac histology, function, and survival to their female HCM littermates. Remarkably, dietary modification from a soy-based diet to a casein-based diet significantly improved survival in HCM/GSK-3 males. These findings indicate that activation of GSK-3 is sufficient to limit cardiac growth in this HCM model and the consequence of caGSK-3 was sexually dimorphic. Furthermore, these results show that blocking hypertrophy by active GSK-3 in this HCM model is not therapeutic.

cardiac hypertrophy; glycogen synthase kinase-3; myosin heavy chain

This article has been cited by other articles:

				S. Hirotani, P. Zhai, H. Tomita, J. Galeotti, J. P. Marquez, S. Gao, C. Hong, A. Yatani, J. Avila, and J. Sadoshima Inhibition of Glycogen Synthase Kinase 3{beta} During Heart Failure Is Protective Circ. Res., November 26, 2007; 101(11): 1164 - 1174. [Abstract] [Full Text] [PDF]